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Rapid diagnosis of multidrug-resistant tuberculosis (MDR-TB) is essential for the prompt initiation
of effective second-line therapy to improve treatment outcome and limit transmission of this
obstinate disease. A variety of molecular methods that enable the rapid detection of mutations
implicated in MDR-TB have been developed. The sensitivity of the methods is dependent, in
principle, on the repertoire of mutations being detected, which is typically limited to mutations in
the genes rpoB, katG and the promoter region of inhA. In this study, a new reverse hybridization
assay, REBA MTB-MDR (M&D), that probes mutations in the oxyR–ahpC intergenic region, in
addition to those in rpoB, katG and the inhA promoter region, was evaluated. A set of 240
Mycobacterium tuberculosis clinical isolates from patients receiving retreatment regimens was
subjected to conventional phenotypic drug-susceptibility testing (DST) and the REBA MTB-MDR
assay. The nucleotide sequences of the loci known to be involved in drug resistance were
determined for comparison. In brief, the results showed that the REBA MTB-MDR assay efficiently
recognized nucleotide changes in the oxyR–ahpC intergenic region as well as those in rpoB, katG
and the inhA promoter region with higher sensitivity, resulting in an 81.0% detection rate for
isoniazid resistance. Inclusion of the oxyR–ahpC intergenic region in the REBA MTB-MDR assay
improved the overall sensitivity of molecular DST for MDR-TB from 73.1 to 79.9%.
INTRODUCTION
The emergence of Mycobacterium tuberculosis strains
resistant to at least isoniazid (INH) and rifampicin (RIF),
the two most potent components of front-line anti-
tuberculosis (TB) therapy, termed multidrug-resistant TB
(MDR-TB), is a serious cause for concern to TB control
programmes worldwide. Development of MDR-TB sig-
nificantly worsens the prognosis for achieving a durable
cure, presages treatment failure and prolongs the period of
transmission potential. Rapid diagnosis of MDR-TB,
therefore, is essential for the prompt initiation of effective
chemotherapy and the prevention of disease spread.
The development of drug resistance is the result of selection
of random genetic mutations in genes associated with drug
resistance. The mechanism of resistance to RIF involves
missense mutations, small deletions or insertions in the rpoB
gene encoding the b-subunit of RNA polymerase. Studies
from diverse countries have shown that 95–96% of all RIF-
resistant isolates have mutations within an 81 bp ‘core
region’ of rpoB (Ba´rtfai et al., 2001; Cavusoglu et al., 2002;
Herrera et al., 2003; Mani et al., 2001; Telenti et al., 1993;
Yue et al., 2003). In contrast, but perhaps not unexpectedly
given its highly complex mechanism of action, the
mutations causing INH resistance are located in more than
three genes and regions (Barry et al., 1998; Slayden & Barry,
Abbreviations: CI, confidence interval; DST, drug-susceptibility testing;
INH, isoniazid; MDR, multidrug resistant; MT, mutated; RIF, rifampicin;
TB, tuberculosis; UPS, upstream promoter sequence; WT, wild-type.
Journal of Medical Microbiology (2011), 60, 1447–1454 DOI 10.1099/jmm.0.032292-0
032292 Printed in Great Britain 1447
2000). Depending on the sample set analysed, it has been
reported that 50–95% of INH-resistant strains contain
mutations in codon 315 of the katG gene encoding the
catalase-peroxidase (Mokrousov et al., 2002; Musser et al.,
1996; Piatek et al., 2000; Telenti et al., 1997) and 20–35%
harbour mutations in the inhA promoter region (Musser
et al., 1996; Piatek et al., 2000; Telenti et al., 1997).
Moreover, 10–15% of INH-resistant strains have mutations
in the oxyR–ahpC intergenic region, although there is no
direct evidence relating mutation at this region and INH
resistance (Piatek et al., 2000; Telenti et al., 1997).
There has been an increasing interest in the development of
rapid molecular methods for detection of those mutations
associated with drug resistance to replace the conventional
phenotypic drug-susceptibility testing (DST), which is
based on culture and typically requires several months.
PCR-based methods with readouts including line probe
assays, analysis with DNA microarrays and real-time PCR
have been the focus of much recent effort in developing
molecular DST methods to determine resistance to RIF and
INH (Cirillo et al., 2004; Edwards et al., 2001; El-Hajj et al.,
2001; Herrera-Leo´n et al., 2005; van Doorn et al., 2003).
Among the most successful of these molecular diagnostic
methods is the GenoType MTBDRplus assay (Hain Life-
Science), which is based on reverse hybridization of
amplicons containing rpoB, katG and inhA from test strains
to probes carrying specific mutations in these genes. This
DNA line probe assay performs well and offers substantial
promise as a rapid molecular DST methodology (Hillemann
et al., 2007; Ma¨kinen et al., 2006). This kit was designed to
probe mutations only in the katG gene and inhA promoter
region in determining INH resistance; however, approxi-
mately 10–15% of INH-resistantM. tuberculosis strains have
mutations in the oxyR–ahpC intergenic region with
additional mutation of katG outside codon 315.
The aim of this study was to evaluate the impact of
expanding the coverage of polymorphic alleles associated
with drug resistance for the detection of MDR-TB using a
new reverse hybridization assay, REBA MTB-MDR
(M&D), that analyses the oxyR–ahpC intergenic region in
addition to rpoB, katG and the inhA promoter region.
METHODS
M. tuberculosis clinical isolates and DST. The strains used in this
study were obtained from National Masan Hospital or Yonsei
University College of Medicine in South Korea. A total of 240 M.
tuberculosis strains were isolated from TB patients receiving retreat-
ment regimens for TB. DST of these isolates was performed by the
absolute concentration method on Lo¨wenstein–Jensen medium
containing 0.2 mg INH ml21 or 40 mg RIF ml21, as described
previously (American Thoracic Society & Centers for Disease Control
and Prevention, 2000).
Genomic DNA preparation. A loop of fresh M. tuberculosis culture
on Lo¨wenstein–Jensen medium was suspended in 400 ml TE buffer
[10 mM Tris/HCl (pH 8.0), 1 mM EDTA] in a screw-capped
microcentrifuge tube. Following heating at 80 uC for 1 h, the heat-
killed bacteria were centrifuged at 13 400 g for 5 min, and 5 ml of the
supernatant was used for PCR amplification.
PCR amplification and sequencing of genes associated with
drug resistance. A mixture of oligonucleotide primer sets specific to
rpoB, katG, the inhA promoter region and the oxyR–ahpC intergenic
region was supplied with the REBA MTB-MDR kit. Regions of rpoB,
katG, the inhA promoter region and the oxyR–ahpC intergenic region
were amplified by multiplex PCR using the REBA MTB-MDR primer
mixture and the heat-killed bacterial supernatant, prepared as
described above, according to the manufacturer’s instructions. PCR
products verified for the amplification of target DNA by agarose gel
electrophoresis were subjected to DNA sequencing of both strands.
The same PCR products were used for the reverse blot hybridization
assay.
Reverse blot hybridization assay. The REBA MTB-MDR kit
contains 13 probes detecting wild-type (WT) sequences and six
probes recognizing mutated (MT) sequences for the determination of
INH and RIF resistance, as well as one probe specific for M.
tuberculosis (MTB; Table 1) and a mycobacterial genus-specific probe
(Myc; Table 1). Hybridization of the PCR products with the probes
immobilized on a membrane was carried out according to the
manufacturer’s instructions. Briefly, denatured PCR products in 26
SSPE (150 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA)/0.1% SDS
were incubated with REBA MTB-MDR membrane strips at 50 uC on
a Mini-Incubation Tray (Bio-Rad). Following washing with 26
SSPE/0.5% SDS at 65 uC, the strips were incubated with streptavidin-
conjugated alkaline phosphatase in 26 SSPE/0.5% SDS at ambient
temperature, after which they were washed with 50 mM Tris/HCl
(pH 7.5)/150 mM NaCl. The hybridized amplicons carrying biotin
incorporated into the PCR primers were detected by incubating the
strips with nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-
indolyl phosphate in 100 mM Tris/HCl (pH 9.5)/100 mM NaCl/
50 mM MgCl2. The presence of mutations was indicated either by
lack of hybridization to the WT probes and hybridization to the
corresponding MT probes, or simply by lack of hybridization to the
respective WT probe. All experiments were performed in duplicate.
The sensitivity of the REBA MTB-MDR assay was determined as the
proportion of drug-resistant isolates identified by the assay compared
with those determined to be resistant by phenotypic DST, whilst the
specificity was determined as the proportion of drug-susceptible
isolates identified by the assay compared with those determined by
phenotypic DST. These calculations and the 95% confidence intervals
(CIs) were computed using Prism 5 software (GraphPad).
RESULTS
DST and reverse blot hybridization assay
A total of 240 clinical isolates of M. tuberculosis from
Korean patients undergoing retreatment for TB were
included in this study. Of these isolates, 134 were resistant
to both INH and RIF, 40 were resistant only to INH and
two were RIF monoresistant, whilst 64 were susceptible to
both INH and RIF as determined by phenotypic DST
(Table 2). Genotypic analysis of RIF and INH resistance
was carried out using the REBA MTB-MDR assay on all the
clinical isolates. Fig. 1 shows an example of a typical
analysis of six strains. Whilst drug-susceptible M. tuber-
culosis strain H37Rv clearly hybridized to all of the WT
probes and none of the MT probes, other drug-resistant
isolates gave unique hybridization patterns depending on
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the mutations that they were carrying, shown by hybrid-
ization to the MT probes and lack of hybridization to the
WT probes.
Frequency of mutations associated with RIF
resistance
The REBA MTB-MDR assay was able to detect 132/136
RIF-resistant isolates (sensitivity 97%; CI 90.8–98.9) and
showed no mutations in the 104 RIF-susceptible isolates.
These results were fully confirmed by DNA sequencing.
The most frequent point mutation among the 136 RIF-
resistant isolates was observed at codon 531 of the rpoB
gene (66 isolates, 48.5%), with 64 isolates showing a
TCGATTG (SerALeu) nucleotide transition. Two isolates
lacking hybridization signals from the rpoB WT5 probe
were determined to have a TCGATGG (Trp) transversion
by DNA sequencing. Other mutations were detected in
alternative rpoB codons including codon 526 (29 isolates,
21.3%), codon 516 (23 isolates, 16.9%), codons 513 and
533 (six isolates each, 4.4%, respectively), codon 511 (three
isolates, 2.2%), codons 517 and 522 (two isolates each,
1.5%, respectively) and codons 510, 512, 515, 523 and 540
(one isolate each, 0.7%, respectively). A CCA deletion
overlapping codons 516 and 517 was observed in one
isolate (0.7%). Among these isolates with confirmed
mutations, double mutations were detected in 11 isolates.
Four isolates were found not having any mutation in rpoB.
No mutation in the rpoB gene was detected in any of the
104 RIF-susceptible isolates. These mutations were all
identified either by a signal from the specific MT probe and
lack of the corresponding WT signal, or by lack of
hybridization to the respective WT probe (Table 2).
Overall, 14 different hybridization patterns representing
31 different mutation patterns in the rpoB gene were
observed.
Frequency of mutations associated with INH
resistance
Among the 174 INH-resistant isolates, the REBA MTB-
MDR assay detected mutations in at least one of the
resistance-associated regions, katG, the inhA promoter and
the oxyR–ahpC intergenic region, in a total of 141 strains
(81.0% sensitivity, CI 74.4–86.6) and these results were
confirmed by DNA sequencing. By far the majority of these
were detected in the katG gene with a mutation in codon
315, AGCAACC (SerAThr), accounting for 51.1% (89
isolates), and a mutation in codon 315 to AAC (Asn)
representing 2.3% (four isolates). The second most
common site of mutation was in the upstream promoter
sequence (UPS) of inhA, accounting for 26.4% (46
isolates). Forty-one isolates (23.6%) carried a CAT
transition at the 215 position, and four isolates (2.3%)
carried a TAC mutation and one isolate (0.6%) carried a
TAA mutation at the 28 position. Seventeen isolates
(9.8%) carried mutations in the oxyR–ahpC intergenic
region, and one of them had a double mutation in this
region. Among these isolates, eight (4.6%) had mutations
in both katG at codon 315 and the inhA promoter region.
Three isolates (1.7%) had mutations at katG codon 315
and in the oxyR–ahpC intergenic region, whilst four isolates
(2.3%) had mutations in the inhA promoter region and
oxyR–ahpC intergenic regions. Mutations solely in the
Table 1. Probes used in the reverse blot hybridization assay
Probe Sequence (5§A3§) Description
Myc GACGTCGTCGCCACCATCGA Mycobacterial probe
MTB AAACATGTCGGCGAGCCC M. tuberculosis probe
rpoB WT1 AGCCAGCTGAGCCAATTC rpoB codons 509–514 WT
rpoB WT2 ATGGACCAGAACAACCCG rpoB codons 515–520 WT
rpoB WT3 CCGCTGTCGGGGTTGACC rpoB codons 521–525 WT
rpoB WT4 TTGACCCACAAGCGCCGA rpoB codons 524–529 WT
rpoB WT5 CTGTCGGCGCTGGGGC rpoB codons 530–534 WT
rpoB MT1 CTGTTGGCGCTGGGGC rpoB codon 531 (TCGATTG)
rpoB MT2 AAATGTCGGCGCCGGGGCC rpoB codon 533 (CTGACCG)
rpoB MT3 TTCATGTACCAGAACAACCCG rpoB codon 516 (GACATAC)
katG 315 WT CACCAGCGGCATCGAG katG codon 315 AGC WT
katG 315 MT ATCACCACCGGCATCGAG katG codon 315 (AGCAACC)
inhA 15UPS WT CGCGGCGAGACGATAGG inhA UPS 215 WT
inhA 15UPS MT CGCGGCGAGATGATAGG inhA UPS 215 (CAT)
inhA 8UPS WT AAAGATAGGTTGTCGGGGTGACT inhA UPS 28 WT
inhA 8UPS MT GACGATAGGCTGTCGGGG inhA UPS 28 (TAC)
ahpC WT1 GCCGATAAATATGGTGTGATATATCA ahpC 260 to 238 WT
ahpC WT2 CCTTTGCCTGACAGCGACTT ahpC 238 to 218 WT
ahpC WT3 CACGGCACGATGGAATGTC ahpC 217 to +2 WT
ahpC WT4 GCAACCAAATGCATTGTCCGC ahpC +3 to +23 WT
ahpC WT5 TTTGATGATGAGGAGAGTCATGC ahpC +24 to +44 WT
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Table 2. Hybridization patterns of M. tuberculosis clinical isolates by the REBA MTB-MDR assay
+ and – indicate presence and absence of the hybridization signal to the probes, respectively.
Phenotypic
DST
(no. of
isolates)*
rpoB katG 315 inhA
15UPS
inhA 8UPS ahpC No. of
isolates
Interpretation
(no. of
isolates)
WT1 WT2 WT3 WT4 WT5 MT1 MT2 MT3 WT MT WT MT WT MT WT1 WT2 WT3 WT4 WT5
RIFR INHR
(134)
+ + + + 2 + 2 2 2 + + 2 + 2 + + + + + 27 rpoB katG (62)
+ + + + 2 2 + 2 2 + + 2 + 2 + + + + + 3
+ + + + 2 2 + 2 2 2 + 2 + 2 + + + + + 1
+ + + + 2 2 2 2 2 + + 2 + 2 + + + + + 1
+ + + 2 + 2 2 2 2 + + 2 + 2 + + + + + 10
+ + + 2 + 2 2 2 2 2 + 2 + 2 + + + + + 1
+ 2 + + + 2 2 + 2 + + 2 + 2 + + + + + 5
+ 2 + + + 2 2 2 2 + + 2 + 2 + + + + + 10
+ 2 + + + 2 2 2 2 2 + 2 + 2 + + + + + 1
2 + + + + 2 2 2 2 + + 2 + 2 + + + + + 2
+ 2 + + 2 2 + 2 2 + + 2 + 2 + + + + + 1
+ + + + 2 + 2 2 + 2 2 + + 2 + + + + + 15 rpoB inhA (25)
+ + + 2 + 2 2 2 + 2 2 + + 2 + + + + + 5
+ 2 + + + 2 2 + + 2 2 + + 2 + + + + + 1
2 + + + + 2 2 2 + 2 2 + + 2 + + + + + 2
2 + 2 + + 2 2 2 + 2 2 + + 2 + + + + + 1
+ + + + 2 + 2 2 + 2 + 2 2 + + + + + + 1
+ + + + 2 + 2 2 + 2 + 2 + 2 2 + + + + 1 rpoB ahpC (9)
+ + + + 2 + 2 2 + 2 + 2 + 2 + + 2 + + 2
+ + + 2 + 2 2 2 + 2 + 2 + 2 + + 2 + + 2
+ + + 2 + 2 2 2 + 2 + 2 + 2 + 2 + + + 1
+ + 2 + + 2 2 2 + 2 + 2 + 2 + + 2 + + 1
+ + 2 + + 2 2 2 + 2 + 2 + 2 2 + + + + 1
2 + + 2 + 2 2 2 + 2 + 2 + 2 + + 2 + + 1
+ + + + 2 + 2 2 2 + 2 + + 2 + + + + + 3 rpoB katG
inhA (7)
+ + + 2 + 2 2 2 2 + 2 + + 2 + + + + + 1
+ 2 + + + 2 2 2 2 + + 2 2 + + + + + + 1
2 2 + + + 2 2 2 2 + + 2 2 2 + + + + + 1
+ + + + 2 2 + 2 2 2 + 2 2 + + + + + + 1
+ + + + 2 + 2 2 2 + + 2 + 2 2 + + + + 1 rpoB katG
ahpC (2)
2 + + 2 + 2 2 2 2 + + 2 + 2 + + 2 + + 1
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Table 2. cont.
Phenotypic
DST
(no. of
isolates)*
rpoB katG 315 inhA
15UPS
inhA 8UPS ahpC No. of
isolates
Interpretation
(no. of
isolates)
WT1 WT2 WT3 WT4 WT5 MT1 MT2 MT3 WT MT WT MT WT MT WT1 WT2 WT3 WT4 WT5
+ + + + 2 + 2 2 + 2 + 2 2 + + + 2 + + 1 rpoB inhA
ahpC (2)
+ 2 + 2 + 2 2 2 + 2 2 + + 2 + + 2 + + 1
+ + + + 2 + 2 2 + 2 + 2 + 2 + + + + + 11 rpoB (23)
+ + + + 2 2 2 2 + 2 + 2 + 2 + + + + + 1
+ + + 2 + 2 2 2 + 2 + 2 + 2 + + + + + 5
+ 2 + + + 2 2 2 + 2 + 2 + 2 + + + + + 4
2 + + + + 2 2 2 + 2 + 2 + 2 + + + + + 2
+ + + + + 2 2 2 2 + + 2 + 2 + + + + + 1 katG (1)
+ + + + + 2 2 2 + 2 + + + 2 + + + + + 1 inhA (1)
+ + + + + 2 2 2 2 + 2 + + 2 + + + + + 1 katG inhA (1)
+ + + + + 2 2 2 + 2 + 2 + 2 + + + + + 1 No mutation (1)
INHR (40) + + + + + 2 2 2 2 + + 2 + 2 + + + + + 20 katG (20)
+ + + + + 2 2 2 + 2 2 + + 2 + + + + + 9 inhA (9)
+ + + + + 2 2 2 + 2 + 2 + 2 + 2 + + + 1 ahpC (1)
+ + + + + 2 2 2 + 2 2 + + 2 2 + + + + 1 inhA ahpC (1)
+ + + + + 2 2 2 + 2 + 2 + 2 + + + + + 9 No mutation (9)
RIFR (2) + + + + 2 + 2 2 + 2 + 2 + 2 + + + + + 2 rpoB (2)
RIFS INHS (64) + + + + + 2 2 2 + 2 + 2 + 2 + + + + + 64 Nomutation (64)
Total 240
*R, Resistant; S, sensitive.
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oxyR–ahpC intergenic region were observed in ten isolates
(5.8%). There were 33 INH-resistant isolates (19.0%)
without any observed mutations in these loci. The 66 INH-
susceptible isolates did not carry any mutations in these
three regions.
These results could be visualized directly by the dual signal
changes, loss of the WT probe signal and appearance of the
MT probe signal, or only by loss of the WT probe signal, in
all but two cases. One isolate had a CAT change at the
230 position and both WT (C) and MT (T) sequences at
the +2 position in the oxyR–ahpC intergenic region, as
confirmed by DNA sequencing, suggesting a possible
mixed infection. This isolate was determined to be INH-
resistant by the REBA MTB-MDR assay because the CAT
change at the 230 position was detected by a lack of
hybridization signal of the ahpC WT2 probe, whilst the
ahpC WT3 probe still gave the WT pattern. The other
isolate also appeared to be a mixed-infection case that had
WT (C) and MT (T) sequences simultaneously at the 210
position in the oxyR–ahpC intergenic region. Although this
isolate gave a WT pattern by the REBA MTB-MDR assay
for the ahpC WT3 probe, this isolate was still detected as
resistant to INH by the REBA MTB-MDR assay, as it also
had mutation in the inhA promoter region. Overall, 17
different hybridization patterns representing 22 different
mutations at codon 315 of katG, in the inhA promoter
region and in the oxyR–ahpC intergenic region were
observed.
Sensitivity and specificity of REBA MTB-MDR
results
As shown in Table 2, the REBA MTB-MDR assay correctly
identified 107/134 MDR isolates, resulting in an overall
sensitivity of 79.8% (CI 71.8–86.1). Likewise, no mutations
in the four gene regions analysed were detected by the
REBA MTB-MDR assay among the 64 RIF- and INH-
susceptible isolates, resulting in a specificity of 100%. As
already alluded to above, in almost all isolates, the
phenotypic DST patterns could be predicted by the
REBA MTB-MDR assay. The strains that had double
mutations in the same gene, and also showed mutations in
other INH resistance-associated regions, were still detected
as MDR by the REBA MTB-MDR assay. In total, 44
different hybridization patterns representing 59 different
mutations in the rpoB hot-spot region, codon 315 of katG,
the inhA promoter region and the oxyR–ahpC intergenic
region of 107 MDR isolates were detected (Table 2).
DISCUSSION
In this study, we evaluated the utility of incorporating
additional putative resistance-related mutations into a
REBA MTB-MDR assay using a panel of 240 M.
tuberculosis clinical isolates, of which 134 were MDR.
This assay contains both WT and MT probes in the 81 bp
hot-spot region of the rpoB gene, probes for codon 315 of
the katG gene, probes for the 215 or 28 UPS of the inhA
promoter region and WT probes of the intergenic region of
the oxyR–ahpC gene immobilized on a membrane. The
presence of mutations was indicated either by lack of
hybridization to the WT oligonucleotide probes and
hybridization to the corresponding mutant oligonucleotide
probes, or by lack of hybridization to the respective WT
sequence only.
This assay successfully detected 107/134 MDR isolates
including nine MDR isolates with mutations in the rpoB
gene and the oxyR–ahpC intergenic region but not in the
katG or inhA genes. These nine MDR isolates would have
been missed by use of previous methods that do not assess
for the presence of mutations in the oxyR–ahpC intergenic
region. The additional isolates correctly detected
amounted to a 5.7% increase in the INH resistance
detection rate from 75.3 to 81.0%, and a 6.8% increase in
the MDR-TB detection rate from 73.1 to 79.9%. This
increase in the detection rate was achieved by the REBA
MTB-MDR assay due to the inclusion of probes spanning
Fig. 1. Hybridization patterns of M. tuberculosis strains by the
REBA MTB-MDR assay. The probes immobilized on the strip are
indicated on the left. Lanes: 1, clinical isolate carrying an rpoB
mutation at codon 531 (TCGATTG); 2, clinical isolate carrying an
rpoB mutation at codon 516 (GACATAC); 3, clinical isolate
carrying a katG mutation at codon 315 (AGCAACC); 4, clinical
isolate carrying a mutation in the upstream promoter sequence
(UPS) of inhA at the ”15 position (CAT); 5, clinical isolate
carrying a mutation in the oxyR–ahpC intergenic region at the ”39
position (CAT); 6, M. tuberculosis strain H37Rv.
H. Bang and others
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the oxyR–ahpC intergenic region. Compared with the data
from phenotypic DST for these strains, the sensitivity and
specificity of the REBA MTB-MDR assay were determined
to be 79.9 and 100%, respectively. It has been reported
previously that 10–15% of INH-resistant strains have
mutations in the oxyR–ahpC intergenic region with
inactivation of KatG (Piatek et al., 2000; Telenti et al.,
1997). The relationship between INH resistance and
mutations of the oxyR–ahpC intergenic region is not yet
clearly understood. Therefore, future studies of the ten
INH-resistant strains containing mutations only in the
oxyR–ahpC intergenic region will be needed to determine
their precise MICs and to investigate whether they have
additional mutations of the katG gene outside codon 315.
This future study will give more information about the
relationship with INH resistance and mutations in the
oxyR–ahpC intergenic region.
Signals for both WT and MT probes, suggestive of mixed
infection with two distinct strains, one WT and the other a
MT strain, were detected in several cases. These isolates had
another mutation in the same region and had mutations in
other INH resistance-associated regions, and were there-
fore determined to be MDR by the REBA MTB-MDR
assay. Although it is not easy to make a simple recom-
mendation in such cases of mixed infection with resistant
and susceptible M. tuberculosis strains as observed in this
study, or in mixed infections containing M. tuberculosis
and a non-tuberculous mycobacterium (Hillemann et al.,
2007), we favour a conservative approach of reporting such
strains as likely to be resistant after exclusion of
involvement of a non-tuberculous mycobacterium.
The REBA MTB-MDR assay was able to detect 132/136
RIF-resistant isolates and showed no mutations in the 104
RIF-susceptible isolates, and these results were fully
confirmed by conventional DNA sequencing. In general,
mutations in the rpoB gene account for 95–96% of RIF-
resistant M. tuberculosis strains worldwide (Musser, 1995;
Raviglione et al., 1995). Similarly, the REBA MTB-MDR
assay correctly detected 141 INH-resistant isolates out of
174 isolates (81%) determined to be drug resistant by
phenotypic DST, whilst not finding any polymorphisms in
66 INH-susceptible isolates.
In addition to the mixed-infection cases, reverse line
blotting assays will continue to underestimate the true
number of resistant strains because of limitations of
knowledge regarding the genotypic markers of drug
resistance. In this study, we showed that inclusion of a
relatively modest number of additional probes to detect
additional mutations associated with INH resistance in the
oxyR–ahpC intergenic region improved the detection rate
of drug-resistant TB in this patient population from 73.1 to
79.9%, which is an improvement over previously imple-
mented line probe assays. This assay is being evaluated on
clinical specimens to determine its potential for improving
rapid diagnosis of MDR-TB in a prospective clinical trial.
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